Jan 9, 2014

PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned

Double-Bottom Line Company Intends to Bring Single-Dose Oral Cholera Vaccine to Travelers' Market First, Then to Developing World Menlo Park, Calif., – January 9, 2014 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially...


Dec 4, 2013

PaxVax Secures $22 Million Series B Financing

Proceeds to Fund Oral Cholera Vaccine Candidate Phase 3 Program Menlo Park, Calif., – December 4, 2013 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has completed...


Sep 6, 2013

PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine

New Vaccine Candidate, If Approved, Will Be the Only Cholera Vaccine Available in the US Menlo Park, Calif., – September 6, 2013 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today...


Jan 31, 2013

PaxVax Announces Positive Results for Oral Ad4 Vaccine Technology

Phase One Study of Oral Replicating Vaccine for H5N1 Published in Lancet Infectious Diseases Menlo Park, Calif., – January 31, 2013 – PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced...


Nov 14, 2012

PaxVax Presents Phase 1 Clinical Trial Data for Single-Dose Cholera Vaccine

Vaccine Candidate Found to be Well Tolerated and Immunogenic Menlo Park, Calif., and Atlanta – November 14, 2012 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a...


Mar 19, 2012

FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine

Company to Begin Phase 3 Trials for First Cholera Vaccine Candidate in U.S. Menlo Park, Calif. – March 19, 2012 – PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and...


Feb 9, 2012

PaxVax Expands Executive Management Team

Accomplished Vaccine Industry Executives Appointed to COO, CTO, and CSO Positions Menlo Park, Calif. – February 9, 2012 – PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced the expansion of its executive management team...


3 of 3123